From: Rafal Smigrodzki (rms2g@virginia.edu)
Date: Thu Feb 13 2003 - 13:03:21 MST
gts wrote:
> Here is yet more evidence that selegiline (deprenyl) may increase
> life-expectancy in humans.
>
> In this study, treated animals enjoyed a 34% increase in life span.
### The study provides evidence that rats on selegiline live longer. Whether
the same applies to humans, is a matter of conjecture, which is why I agree
with your use of "may", as in "maybe yes, maybe not".
Rafal
>
> ABSTRACT:
> Deprenyl increases the life span as well as activities of superoxide
> dismutase and catalase but not of glutathione peroxidase in selective
> brain regions in Fischer rats
>
> Kitani K, Kanai S, Carrillo MC, Ivy GO
>
> Radioisotope Research Institute,
> Faculty of Medicine,
> University of Tokyo, Japan.
> Ann N Y Acad Sci 1994 Jun 30; 717:60-71
>
> ABSTRACT
>
> (-)Deprenyl, a MAO-B inhibitor that is also known to be effective for
> symptoms of Parkinson's disease, when injected subcutaneously (sc) in
> male Fischer-344 rats at a dose of 0.5 mg/kg per day (3 times a week)
> from 18 months of age, significantly increased the remaining life
> expectancy. The average life span after 24 months was 34% greater in
> treated rats than in saline-treated control animals. Furthermore, a
> short-term (3 wk) continuous sc infusion of deprenyl significantly
> increased activities of superoxide dismutase and catalase but not of
> glutathione peroxidase in selective brain regions such as s. nigra,
> striatum, and cerebral cortex, but not in hippocampus or cerebellum,
> or the liver. The optimal dose for increasing these activities,
> however, differed greatly depending on the sex and age of animals,
> with a 10-fold lower value for young female than male rats.
> Interestingly, aging caused an increase and a decrease in the optimal
> dose in female and male rats, respectively. In addition, treatment
> for a longer term tended to reduce the optimal dosage in the same
> animal group. The results clearly demonstrate that deprenyl increases
> antioxidant enzyme activities in selective brain regions. If this
> effect of deprenyl is causally related to its life-prolonging effect,
> the dosage to be used for any life span study would be a critical
> factor, with the dosage differing widely depending on sex, age of
> animal, and mode and duration of drug administration.
This archive was generated by hypermail 2.1.5 : Thu Feb 13 2003 - 12:55:36 MST